ArticleJournal of medicinal chemistry2023
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 53 citations in OpenAlex.
- SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.Antimicrobial agents and chemotherapy · 2025Trial
- No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials.Viruses · 2024Trial
- Identification of key metabolic enzymes involved in the activation of obeldesivir and remdesivir to the active triphosphate metabolite.Antimicrobial agents and chemotherapy · 2026Article
- Pharmacokinetics, Safety, and Tolerability of Obeldesivir in Healthy Japanese and White Participants.European journal of drug metabolism and pharmacokinetics · 2026Article
- Antivirals Targeting Coronavirus RNA-Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID-19 Clinical Trials.Microbial biotechnology · 2026Review
- Antiviral Profiling and Cellular Activation of Carbobicyclic Nucleoside Analogues.Journal of medicinal chemistry · 2026Article
- Article
- Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI.Frontiers in digital health · 2026Article
- Status of advanced respiratory syncytial virus antiviral therapeutics 2025.Current opinion in virology · 2025Review
- 1'-Cyanocytidine-5'-isobutyryl is a potent SARS-CoV-2 inhibitor in culture and infected Syrian hamsters.Science advances · 2025Article
- SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance.Viruses · 2025Article
- Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys.Nature communications · 2025Article
- Article
- Remdesivir postexposure prophylaxis limits measles-induced "immune amnesia" and measles antibody responses in macaques.JCI insight · 2025Article
- Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates.Nature medicine · 2025Article
- Article
- The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection.Science advances · 2025Article
- Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics.Clinical microbiology reviews · 2025Review
- Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants.Viruses · 2025Article
- The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.Antiviral research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 3 institutions in 1 country.
Richard L MackmanMedicinal Chemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.ORCID 0000-0001-8861-7205
Rao V KallaMedicinal Chemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Darius BabusisDrug Metabolism, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Jared PittsDiscovery Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Kimberly T BarrettFormulation and Process Development, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.ORCID 0000-0003-4128-8437
Kwon ChunMedicinal Chemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Venice Du PontDiscovery Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Lauren RodriguezClinical Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Jasmine MoshiriClinical Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Yili XuBiochemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Michael LeeBiology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Gary LeeBiology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Blake BleierFormulation and Process Development, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Anh-Quan NguyenFormulation and Process Development, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
B Michael O'KeefeProcess Chemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.ORCID 0009-0002-8355-8597
Andrea AmbrosiProcess Chemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.ORCID 0000-0002-2889-5913
Meredith CookProcess Chemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Joy YuProcess Chemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Kassibla Elodie DempahProcess Development, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.ORCID 0000-0002-5204-9290
Elaine BunyanProcess Development, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Nicholas C RiolaDiscovery Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Xianghan LuDiscovery Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Renmeng LiuDrug Metabolism, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Ashley DavieDrug Metabolism, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Tien-Ying HsiangCenter for Innate Immunity and Immune Disease, Department of Immunology, School of Medicine, University of Washington, Seattle, Washington 98109 United States.
Justin DearingLovelace Biomedical Research Institute, 2425 Ridgecrest Drive Southeast, Albuquerque, New Mexico 87108 United States.
Meghan VermillionLovelace Biomedical Research Institute, 2425 Ridgecrest Drive Southeast, Albuquerque, New Mexico 87108 United States.
Michael GaleCenter for Innate Immunity and Immune Disease, Department of Immunology, School of Medicine, University of Washington, Seattle, Washington 98109 United States.
Anita Niedziela-MajkaBiology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Joy Y FengBiochemistry, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Charlotte HedskogClinical Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
John P BilelloDiscovery Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Raju SubramanianDrug Metabolism, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.ORCID 0000-0002-3806-5227
Tomas CihlarDiscovery Virology, Gilead Sciences Incorporated, 333 Lakeside Drive, Foster City, California 94404 United States.
Gilead Sciences (United States) · USLovelace Respiratory Research Institute · USUniversity of Washington · US
Funding
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2MNIAID NIH HHS UM1 AI148684
Abstract
Remdesivir
Indexed as
COVID-19ProdrugsAdenosineAnimalsAntiviral AgentsChlorocebus aethiopsCOVID-19 Drug TreatmentFuransHumansNucleosidesRNA, ViralSARS-CoV-2AdenosineAntiviral AgentsFuransGS-441524NucleosidesProdrugsRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.